A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease

Hepatic stellate cells (HSCs) are an important cellular target for the development of novel pharmacological therapies to prevent and treat nonalcoholic fatty liver diseases (NAFLD). Using a high fat diet (HFD) model of NAFLD, we sought to determine if synthetic selective agonists for retinoic acid r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of molecular medicine (Berlin, Germany) Germany), 2016-10, Vol.94 (10), p.1143-1151
Hauptverfasser:	Trasino, Steven E., Tang, Xiao-Han, Jessurun, Jose, Gudas, Lorraine J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Benzoates - pharmacology Benzoates - therapeutic use Biomedical and Life Sciences Biomedicine Cytokines - genetics Diet, High-Fat Hepatic Stellate Cells - drug effects Hepatic Stellate Cells - metabolism Human Genetics Internal Medicine Liver - drug effects Liver - metabolism Liver - pathology Male Mice, Inbred C57BL Molecular Medicine Naphthols - pharmacology Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - pathology Original Article Oxidative Stress - drug effects Receptors, Retinoic Acid - agonists Retinoic Acid Receptor gamma Thiazoles - pharmacology Thiazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!